Synonym: B-type natriuretic peptide
Brain natriuretic peptide (BNP) levels increase markedly in left ventricular dysfunction and the level in heart failure correlates with symptom severity. BNP is therefore an important clinical marker for the diagnosis of heart failure in patients with unexplained dyspnoea. Other clinical applications, such as screening for asymptomatic ventricular dysfunction, establishing the prognosis or guiding the titration of drug therapy and prediction of future cardiovascular events, are under investigation but have not yet been sufficiently validated for widespread clinical use.
BNP is a biologically active peptide of 32 amino acids and has vasodilator and natriuretic properties. BNP is cleaved from the 108-amino acid pro-brain natriuretic peptide released from the cardiac ventricles in response to stretching of the chamber. The second remnant after cleavage, N-terminal pro-brain natriuretic peptide (NT-proBNP), is a 76-amino acid peptide with no known biological function which circulates at higher concentrations than BNP and may represent cardiac status over longer periods.
The release of BNP appears to be in direct proportion to ventricular volume expansion and pressure overload. BNP increases with right or left systolic or diastolic heart failure. It is an independent predictor of high left ventricular end-diastolic pressure. BNP levels decrease after effective treatment of heart failure.
Although testing for BNP provides a useful adjunct to routine assessment for differentiating acute heart failure from other causes of breathlessness, other factors such as comorbid illnesses, age, renal failure and body mass may affect BNP levels in ways that can obscure the diagnosis of heart failure, particularly when this marker is used in isolation. Therefore it is essential that BNP be used to aid diagnosis in addition to the patient's history, clinical signs and other investigations.
- Add notes to any clinical page and create a reflective diary
- Automatically track and log every page you have viewed
- Print and export a summary to use in your appraisal
There is currently no definite evidence of a clinical advantage between using either brain natriuretic peptide (BNP) assay or N-terminal pro-brain natriuretic peptide (NT-proBNP) assay.
- The most commonly used decision threshold for BNP is 100 pg/ml.
- BNP levels of more than 100 pg/ml have a greater than 95% specificity and greater than 98% sensitivity when comparing patients without congestive heart failure (CHF) to all patients with CHF.
- Even BNP levels of more than 80 pg/ml have a greater than 93% specificity and 98% sensitivity in the diagnosis of heart failure.
- BNP levels rise with age. Mean BNP levels are:
- 26.2 pg/ml in those aged 55-64 years.
- 31.0 pg/ml in those aged 65-74 years.
- 63.7 pg/ml in those aged 75 years and older.
- Women without CHF tend to have higher BNP levels than males of the same age.
Patients should have had an ECG, chest X-ray, full blood count, renal function and electrolytes tests, liver function tests, lipid profile, thyroid function tests and any other investigation relevant to the clinical presentation.
Potential causes of elevated brain natriuretic peptide levels
Potential use of brain natriuretic peptide measurement
Assay of brain natriuretic peptide (BNP) is a potential aid in the diagnosis of heart failure. BNP testing allows a rapid assessment for defining those patients warranting an echocardiogram and also has the potential to enable rapid changes in therapy for those already receiving treatment for heart failure.
- BNP testing is effective in screening for left ventricular systolic dysfunction and reduces the number of patients requiring an echocardiogram.
- BNP levels correlate closely with the New York Heart Association (NYHA) Classification of Heart Failure as well as the Goldman Specific Activity Scale of Heart Failure.
- Normal concentrations virtually exclude the diagnosis of heart failure, and very high levels effectively diagnose the condition; intermediate values require further evaluation.
- Assay of BNP has potential as part of a diagnostic triage in patients presenting with symptoms suggestive of heart failure or in screening populations at high risk.
- In several pilot studies, BNP levels had a strong correlation with the severity of illness and were very reliable in differentiating heart failure from pulmonary disease.
In a pilot study, BNP levels correlated highly with clinical outcomes:
- Patients with decreased BNP levels during their hospital stay, along with decreases in NYHA classification, had good outcomes.
- Patients whose hospital stay ended in death or readmission within 30 days of discharge had only minimal decreases of BNP levels or rising levels of BNP despite improvement or no change in their NYHA classification.
- The last measured BNP level was the single most reliable variable in predicting short-term outcomes in patients with heart failure.
Other potential clinical applications
- Raised plasma natriuretic peptide levels have been shown to predict the risk of death and cardiovascular events in people without heart failure after adjustment for traditional risk factors. Excess risk was apparent at natriuretic peptide levels well below current thresholds used to diagnose heart failure.
- Natriuretic peptides may help in identifying people at risk of stroke and atrial fibrillation.
- Admission BNP is an independent and powerful marker of early and late cardiac mortality in patients with acute chest pain without ST-segment elevation.
Further reading & references
- The use of B-type natriuretic peptides (BNP and NT-proBNP) in the investigation of patients with suspected heart failure, NHS Quality Improvement Scotland (2005)
- Management of chronic heart failure in adults in primary and secondary care, NICE (July 2003)
- Heart failure - chronic, Clinical Knowledge Summaries (June 2009)
- Ray SG; Natriuretic peptides in heart valve disease. Heart. 2006 Sep;92(9):1194-7. Epub 2005 Oct 26.
- Jankowski M; B-type natriuretic peptide for diagnosis and therapy. Recent Pat Cardiovasc Drug Discov. 2008 Jun;3(2):77-83.
- Hobbs FD, Davis RC, Roalfe AK, et al; Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ. 2002 Jun 22;324(7352):1498.
- NHS Heart Improvement Programme; Brain-type Natriuretic Peptide (BNP).; June 2008.
- Schreiber D, Nix DA; Natriuretic Peptides in Congestive Heart Failure; eMedicine, December 2008.
- Felker GM, Petersen JW, Mark DB; Natriuretic peptides in the diagnosis and management of heart failure. CMAJ. 2006 Sep 12;175(6):611-7.
- Nielsen OW, McDonagh TA, Robb SD, et al; Retrospective analysis of the cost-effectiveness of using plasma brain J Am Coll Cardiol. 2003 Jan 1;41(1):113-20.
- Sim V, Hampton D, Phillips C, et al; The use of brain natriuretic peptide as a screening test for left ventricular Fam Pract. 2003 Oct;20(5):570-4.
- NHS Economic Evaluation Database (NHS EED); Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population.
- Wang TJ, Larson MG, Levy D, et al; Plasma natriuretic peptide levels and the risk of cardiovascular events and N Engl J Med. 2004 Feb 12;350(7):655-63.
- Kurl S, Ala-Kopsala M, Ruskoaho H, et al; Plasma N-terminal fragments of natriuretic peptides predict the risk of stroke Heart. 2009 Jul;95(13):1067-71. Epub 2009 Mar 24.
- Bassan R, Tura BR, Maisel AS; B-type natriuretic peptide: a strong predictor of early and late mortality in Coron Artery Dis. 2009 Mar;20(2):143-9.
|Original Author: Dr Colin Tidy||Current Version: Dr Colin Tidy|
|Last Checked: 22/01/2010||Document ID: 3018 Version: 22||© EMIS|
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.